Menu
Menu

"After raising $85m, SutroVax contracts Lonza to support vaccine development"

"Lonza is supporting SutroVax’s development of its pneumococcal conjugate vaccine candidate through an end-to-end supply relationship."

January 0001

"As Lonza and SutroVax's partnership moves forward, we will continue to work closely together and ensure alignment on process and conjugate development, as well as microbial manufacturing scale-up for drug substance at Lonza's Visp, Switzerland site." said Karen Fallen, VP at Lonza